Dasarahalli N Vijayraghav
Dasarahalli N Vijayraghav has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anilkumar Dandu
Connexios Life Sciences Pvt Ltd, Bangalore, India
1 shared publication - Anup Mammen Oommen
Glycoscience Group, NCBES National Centre for Biomedical Engineering Science, National University of Ireland Galway, Galway, Ireland
1 shared publication - Baggavalli P Somesh
Connexios Life Sciences Private Ltd., No. 49, First Main road, 3rd phase, JP Nagar, Bangalore, 560 078, India
1 shared publication - Bhawna Chandravanshi
Manipal University, KA, India
1 shared publication - Jaideep Singh
Connexios Life Sciences Pvt Ltd, #49, “SHILPA VIDYA” 1st Main, 3rd Phase, JP Nagar, Bangalore 560078, India
1 shared publication - Jayalaxmi Shetty
AB Shetty Memorial Institute of Dental Sciences, Nitte (Deemed to be University), Deralakatte, Mangalore 575018, Karnataka, India
1 shared publication
Latest Publications
- Open Access
- 25 March 2014
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 15 (1) , 19
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
GPR40 is a G-protein coupled receptor regulating free fatty acid induced and also glucose induced insulin secretion. We generated neonatally-streptozotocin-treated female rats (n-STZ) and treated them with CNX-011-67, a GPR40 agonist to examine the role of GPR40 in modulation of glucose metabolism, insulin secretion and content.
- 25 March 2014
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 15 (1) , 19
Open AccessCNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
GPR40 is a G-protein coupled receptor regulating free fatty acid induced and also glucose induced insulin secretion. We generated neonatally-streptozotocin-treated female rats (n-STZ) and treated them with CNX-011-67, a GPR40 agonist to examine the role of GPR40 in modulation of glucose metabolism, insulin secretion and content.